Fulcrum Therapeutics (FULC) Equity Average (2019 - 2026)
Fulcrum Therapeutics (FULC) has disclosed Equity Average for 7 consecutive years, with $273.7 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 9.4% to $273.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $273.7 million through Dec 2025, up 9.4% year-over-year, with the annual reading at $296.0 million for FY2025, 23.8% up from the prior year.
- Equity Average for Q4 2025 was $273.7 million at Fulcrum Therapeutics, up from $206.4 million in the prior quarter.
- The five-year high for Equity Average was $285.8 million in Q2 2023, with the low at $111.5 million in Q1 2021.
- Average Equity Average over 5 years is $218.2 million, with a median of $222.9 million recorded in 2024.
- The sharpest move saw Equity Average skyrocketed 120.89% in 2021, then dropped 22.28% in 2025.
- Over 5 years, Equity Average stood at $221.1 million in 2021, then decreased by 4.93% to $210.2 million in 2022, then grew by 16.72% to $245.3 million in 2023, then rose by 1.97% to $250.2 million in 2024, then increased by 9.4% to $273.7 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $273.7 million, $206.4 million, and $221.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.